I

: 616.015.348:616.699-078.73-091.7

.. , ..

, .
: , Ubiquitin Ubiquitin SUMO.
Ubiquitin Ubiquitin SUMO 28
- . -
, ,
. -

, ,
.

.. , ..
Ubiquitin Ubiquitin SUMO 28
- . , ,
. -

,
, .
: , Ubiquitin Ubiquitin SUMO.
. 2011. .8, 3. . 3539

Ubiquitination and sumoilation processes in pathogenesis of male infertility

S.V. Bazalytska, A.M. Romanenko
Immunohistochemical features of expression of proteins Ubiquitin and Ubiquitin SUMO in testicular tissue of 28 patients with serious forms of male infertility excretory-obstructive and secretory ones are studied. The molecular changes of Ubiquitin-proteasome
system typical for male infertility, testify to the raised contents of the damaged intracellular proteins in cells. The changes of Ubiquitinproteasome system in the secretory form of male infertility testify to intensifying of ubiquitination and sumoilation processes in Sertoli
cells and about disturbance of these processes in interstitial endocrinocyties Leydig cells, which carry out the basic regulating influence
on spermatogenesis, that is a basis of development of male infertility in such patients.
Key words: male infertility, Ubiquitin and Ubiquitin SU proteins.
Pathologia. 2011; 8(3): 3539

2004
,
-,

.
,
-
:
, -
, ,

, ,
,
[1].
, ubiquitin protein ligase,
,

[24]. , ,

.

Ubiquitin Ubiquitin SUMO
.

28 ,
,

.
[5].

.
3
:
1 11 ,
- .
33,6 .
2 12 ,

.. , .. , 2011
, 2011, .8, 3

35

.. , ..

, 1 2
. 29,5 .
3 5 ,

. 28,5 .

.
5 ,
-.
()
-
.
12% ,
5 .
Ubiquitin (DAKO, Glostrup,
) 1:800 Ubiquitin SUMO (DAKO,
Glostrup, ) 1:400. 12 0,05%
(DAB),
.

Ubiquitin Ubiquitin
SUMO. ,
.
- 1216
. -
[6].

0 3
: 0
, 1 10% , 2
10%, 50% , 3
50%
.
: 0
, 1
, 2 ,
3 .
-
() 0 9 ,

.
.

Ubiquitin
-

(: 13)
4 (45%), 6 (55%) (: 46).
5,10,45.
Ubiquitin
(: 13) (100%).
2,70,09 (. 1).
,
1 2 ,
Ubiquitin

36

(100%) ,
23 .
2,30,09 2,20,09 .
,
Ubiquitin (: 0)
(100%).
6
3 (27%); 6
(54,5%) (:
13) 2 (18%)
Ubiquitin (: 0).
4,30,54. (: 23)
9 (81%) (. 1),
2 (19%) (: 0). 2,70,27 (. 1).
1
Ubiquitin
xx

2,30,09
2,20,09

2,60,17
2,60,17

2,30,09
2,20,09

2,10,17
1,90,17

2,20,09
2,20,09

2,10,17
2,20,17

5,10,45
2,70,09*,**

5,80,17
4,80,17*

5,90,4
7,40,6*,**

4,30,54*,**
2,70,27*,**

0,30,16*
4,90,08*

0,30,2**
5,60,6**

0
0

: *, ** ; 0,001.

, 1
2 ( 12 ),

(: 46) 12 (100%).
5,80,17.
Ubiquitin
(: 23) 4 (33,3%)
(: 46) 8 (66,7%).
4,80,17.
,
1 2 ,
Ubiquitin
(100%) ,
13 .

2,10,17 2,20,17; 2,10,17
1,90,17; 2,60,17 2,60,17.
, 2011, .8, 3

Ubiquitin
(: 0) 9 (75%) 3 (25%) (: 13).
0,30,16. , 6 (50%)

(: 23), 6 (50%)

(: 46) (. 2).
4,90,08 (. 1).

( 5 ),

(: 46) (100%).
5,90,4.
Ubiquitin (: 6) 3 (60%)
2 (40%).
7,40,6.

(: 0) 4 (80%),
(20%)
(: 1). 0,30,2.
, 4 (80%)
(: 46)
(20%)
(: 3) (. 3).
5,60,6 (. 1).
, - Ubiquitin


,
- ;



.
SUMO
-
,
(: 1)
1 (10%), 10 (90%)
SUMO (: 0).
0,10,009 (. 2).
SUMO
(: 0) (100%).
,
1 2 ,

SUMO (:0)
(100%) .
10 (90%)
(: 13), 1
(10%)
SUMO (: 4).
3,40,54.
SUMO (: 13)
, 2011, .8, 3

2

Ubiquitin SUMO xx

0
0

0
0

1,30,08
1,30,08

0
0

1,30,08
1,30,08

0
0

1,30,08
1,30,08

0,10,09
0

1,80,17*
1,70,17*

5,80,4
7,50,6

3,40,54
1,10,27

0,90,17
1,40,17*

0
1,30,4**

: *, ** ; 0,001.

9 (81%) ,
2 (19%) (: 0)
1,10,27 (. 4).

,
1 2
(: 13)
12 (100%).
1,80,17.
SUMO
(: 13) 12 (100%).
1,70,17.
,
1 2 ,

SUMO (100%) ,
12 .
, 1
2
1,30,08 (. 2).
SUMO
(: 0) 6 (50%),
6 (50%)
(: 13).
0,90,17 (. 2, . 5).


(:
46) (100%).
5,80,4.
SUMO
(: 46) 4 (80%),

37

.. , ..

(20%)
SUMO (: 9).
7,50,6.

SUMO (: 0) 5
(100%), (100%)
(: 13)
1,30,4 (. 2, . 6).
,
SUMO

,
SUMO
,
- .
, - (UBL)
,
,
.
11 - .
UBL SUMO, ,
, .
SUMO ,
[1].
, - ,
: )
; )
; ) ; ) ,
.
,

. , , -,
; -,
,
.
,
,
,
2 : 1)
,
; 2) .
, ,
, , ,

.

. 3
: 1- (), 2-
(, ), 3- (),

,
[1,7]. ,
,
48- (
11-, 29- 63- ).

38

. .
-
.
,
, ,
,
.
-,
.

:
,
[9].

, :
[9]. ,
,
.
in vitro. ,

.
,
,


.
, -
, ,

.

1. Ubiquitin


,
- ;


.
2.
Ubiquitin SUMO

,
- , Ubiquitin SUMO
,
- .
3. -
,
,
- .
: )
,
, 2011, .8, 3

, ,


; )
Ubiquitin Ubiquitin SUMO
,

.
4. -


,
,
.
,
.

1.

Ciechanover A. The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanismbased drug targeting / Ciechanover A. // Biochem. Soc. Trans.
2003. Vol. 31, 2. P. 474485.

2.

3.

4.

5.
6.

7.
8.

9.

Ng J.M. Developmental defects and male sterility in mice

lacking the ubiquitin-like DNA repair gene mHR23B / Ng
J.M., Vrieling H., Sugasawa K., Ooms M.P., et al. // Mol. Cell.
Biol. 2002. Vol. 22, 4. P. 12331245.
Sutovsky P. Ubiquitin-dependent proteolysis in mammalian
spermatogenesis, fertilization, and sperm quality control: killing three birds with one stone / Sutovsky P. // Microsc. Res.
Tech. 2003. Vol. 61, 1. P. 88102.
Bedard N. Mice lacking the UBC4-testis gene have a delay
in postnatal testis development but normal spermatogenesis
and fertility / Bedard N., Hingamp P., Pang Z., Karaplis A.,
Morales C., Trasler J., Cyr D., Gagnon C., Wing S.S. // Mol.
Cell. Biol. 2005. Vol. 25, 15. P. 63466354.
.. / ..,
.., .. .: , 1990.
464 .
Malmstrum P.U. Expression of ABH blood group isoantigen
as a prognostic factor in transitional cell bladder carcinoma
/ Malmstrum P.U., Busch C., Norben B.J., Andersson B. //
Scand. J. Urol. Nephrol. 1998. Vol. 22. P. 265270.
Ciechanover A. The ubiquitin-proteasome pathway: on protein
death and cell life / Ciechanover A. // EMBO J. 1998. V.
17, 24. P. 71517160.
Glickman M.H. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction / Glickman
M.H., Ciechanover A. // Physiol Rev. 2002. 82. P.
373428.
Turner G. Peptides accelerate their uptake by activating a
ubiquitin-dependent proteolytic pathway / Turner G., Du F.,
Varshavsky A. // Nature. 2000. V. 405. P. 579582.

:
.., .
.., . .
:
. 04053, . , . , 9.
.: (044) 486 96 52.
-mail: svetlana_bazalic@inbox.ru

, 2011, .8, 3

39